Agenus Inc logo

AGEN

Agenus Inc

$2.76

Earnings Summary

Revenue
$25.94Mn
Net Profits
$-48.33Mn
Net Profit Margins
-186.29%
PE Ratio
13.55

Highlights

Revenue:

Agenus Inc’s revenue jumped 121.36% since last year same period to $25.94Mn in the Q1 2022. On a quarterly growth basis, Agenus Inc has generated 28.03% jump in its revenue since last 3-months.

Net Profits:

Agenus Inc’s net profit jumped 9.97% since last year same period to $-48.33Mn in the Q1 2022. On a quarterly growth basis, Agenus Inc has generated 31.27% jump in its net profits since last 3-months.

Net Profit Margins:

Agenus Inc’s net profit margin jumped 59.33% since last year same period to -186.29% in the Q1 2022. On a quarterly growth basis, Agenus Inc has generated 46.31% jump in its net profit margins since last 3-months.

PE Ratio:

Agenus Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 13.55.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Agenus Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Agenus Inc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 23.33% jump from last quarter’s estimates.

EPS Estimate Current Year:

Agenus Inc’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Agenus Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.19
Return on Assets (ROA)
0.1
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Agenus Inc’s earning per share (EPS) jumped 29.63% since last year same period to -0.19 in the Q1 2022. This indicates that the Agenus Inc has generated 29.63% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Agenus Inc’s return on assets (ROA) stands at 0.1.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Agenus Inc’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Agenus Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.3
-0.19
36.67%

Company Information

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.

Organisation
Agenus Inc
Headquarters
3 Forbes Road, Lexington, MA, United States, 02421-7305
Employees
359
Industry
Health Technology
CEO
Garo Armen